The Desmopressin melt therapy in children with non-monosymptomatic nocturnal enuresis: a prospective study


  • Thaweesub Chaikaew Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • Jaraspong Vuthiwong Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
  • Phitsanu Mahawong Division of Urology, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand



Desmopressin, melt, children, non-monosymptomatic, nocturnal enuresis


Objective: The negative consequences of enuresis in children can be far reaching and an understanding of the impact of these is essential for effective treatment by the clinician. Enuresis can be categorized into monosymptomatic nocturnal enuresis (MNE) and non-monosymptomatic nocturnal enuresis (NMNE). There have been several studies in treatment of MNE with lyophilizate desmopressin melt but very limited research into the efficacy of desmopressin melt in treating NMME. The objectives of this study were to measure the efficacy and side effects of desmopressin melt in treating children with NMNE.

Materials and Methods: Children aged 6 to 18 years with NMNE who visited the outpatient department of pediatric urology were included in this prospective study. Any underlying diseases and lower urinary tract symptoms were corrected then their enuresis was treated with 120-240 mcg of desmopressin melt for 6-8 weeks. Outcomes were defined as complete response, partial response, and no-response as defined by the International Children’s Continence Society guidelines.

Results: A total of 25 children with NMNE were included in the study. The results showed 44% complete response, 20% partial response, and 36% no-response. The mean volume of nocturnal enuresis decreased from 159.96 to 115.30 ml in the pre and post treatment periods, respectively (p = 0.012). The mean frequency of enuresis decreased from 4.36 to 2.84 days per week in pre and post treatment periods, respectively (p < 0.001). The mean whole night urine volume decreased from 373.39 to 292.37 ml in pre and post treatment periods (p = 0.061). There were no major side effects in the study.

Conclusion: Desmopressin melt is effective and safe in treating NMNE in children. However, to add weight to the findings of this study further research with a larger number of patients should be considered in the near future.


Austin PF, Bauer SB, Bower W, Chase J, Franco I, Hoebeke P, et al. The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn 2016;35:471-81.

Hansakunachai T, Ruangdaraganon N, Udomsubpayakul U, Sombuntham T, Kotchabhakdi N. Epidemiology of Enuresis Among School-Age Children in Thailand. J Dev Behav Pediatr 2005;26:356-60.

Fergusson DM, Horwood LJ, Shannon FT. Factors Related to the Age of Attainment of Nocturnal Bladder Control: An 8-Year Longitudinal Study. Pediatrics 1986;78:884-90.

Bakker E, Sprundel Mv, Auwera JCvd, Gool JDv, Wyndaele JJ. Voiding Habits and Wetting in a Population of 4332 Belgian Schoolchildren Aged Between 10 and 14 Years. Scand J Urol Nephrol 2002;36:354-62.

Ertan P, Yilmaz O, Caglayan M, Sogut A, Aslan S, Yuksel H. Relationship of sleep quality and quality of life in children with monosymptomatic enuresis. Child Care Health Dev 2009;35:469-74.

Robson WLM. Evaluation and Management of Enuresis. N Engl J Med 2009;360:1429-36.

Joinson C, Heron J, Butler R, Von Gontard A, Butler U, Emond A, et al. A United Kingdom Population-Based Study of Intellectual Capacities in Children With and Without Soiling, Daytime Wetting, and Bed-wetting. Pediatrics 2007;120:e308-16.

Carskadon MA. Sleep deprivation: health conse- quences and societal impact. Med Clin North Am 2004;88:767-76.

Pugner K, Holmes J. Nocturnal enuresis: economic impacts and self-esteem preliminary research results. Scand J Urol Nephrol Suppl 1997;183:65-9.

Butler R, McKenna S. Overcoming parental intolerance in childhood nocturnal enuresis: a survey of professional opinion. BJU Int 2002;89:295-7.

Sapi MC, Vasconcelos JS, Silva FG, Damiao R, Silva EA. Assessment of domestic violence against children and adolescents with enuresis. J Pediatr (Rio J). 2009;85:433-7.

Schulpen TW. The burden of nocturnal enuresis. Acta Paediatr 1997;86:981-4.

Lordelo P, Benevides I, Kerner EG, Teles A, Lordelo M, Barroso U, Jr. Treatment of non-monosymptomatic nocturnal enuresis by transcutaneous parasacral electrical nerve stimulation. J Pediatr Urol 2010;6:486-9.

DiBianco JM, Morley C, Al-Omar O. Nocturnal enuresis: A topic review and institution experience. Avicenna J Med 2014;4:77-86.

Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S, et al. Practical consensus guidelines for the management of enuresis. Eur J Pediatr 2012;171:971-83.

SaisaardP,MahawongP,BoonchooduangN,Chon- gruksut W. Quality of life in pediatric patients with lumbosacral myelomeningocele compare to normal children. Thai J Urol 2019;39:10-19.

Rittig S, Schaumburg HL, Siggaard C, Schmidt F, Djurhuus JC. The Circadian Defect in Plasma Vasopressin and Urine Output is Related to Desmopressin Response and Enuresis Status in Children With Nocturnal Enuresis. J Urol 2008;179:2389-95.

Lottmann H, Froeling F, Alloussi S, El-Radhi AS, Rittig S, Riis A, et al. A randomised comparison of oral desmopressin lyophilisate (MELT) and tablet formulations in children and adolescents with primary nocturnal enuresis. Int J Clin Pract 2007;61: 1454-60.

Robson WLM, Leung AKC, Norgaard JP. The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis. J Urol 2007;178:24-30.

Vande Walle JG, Bogaert GA, Mattsson S, Schurmans T, Hoebeke P, Deboe V, et al. A new fast-melting oral formulation of desmopressin: a pharmacodynamic study in children with primary nocturnal enuresis. BJU Int 2006;97:603-9.

Alloussi SH, Murtz G, Lang C, Madersbacher H, Strugala G, Seibold J, et al. Desmopressin treatment regimens in monosymptomatic and nonmonosymptomatic enuresis: A review from a clinical perspective. J Pediatr Urol 2011;7:10-20.

Kurt O, Yazici CM, Paketci C. Nocturnal enuresis with spina bifida occulta: Does it interfere behavioral management success? Int Urol Nephrol 2015;47:1485-91.

Yavuz A, Bayar G, Kilinc MF, Sariogullari U. The Relationship Between Nocturnal Enuresis and Spina Bifida Occulta: A Prospective Controlled Trial. Urology 2018;120:216-21.

Im YJ, Lee JK, Park K. Time Course of Treatment for Primary Enuresis With Overactive Bladder. Int Neurourol J 2018;22:107-13.

Jabbour M, Abou Zahr R, Boustany M. Primary Nocturnal Enuresis: A Novel Therapeutic Strategy With Higher Efficacy. Urology 2019;124:241-7.




How to Cite

Chaikaew, T., Vuthiwong, J., & Mahawong, P. (2021). The Desmopressin melt therapy in children with non-monosymptomatic nocturnal enuresis: a prospective study. Insight Urology, 42(2), 117–122.



Original article